Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BP-101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Enrolled in Ovoca Bio's Phase II Study - BP-101
Details : The double-blind placebo-controlled study is expected to enrol 476 patients across 13 sites. BP-101 is a synthetic peptide administered through a nasal spray and has been supplied for this study by well established peptide manufacturers in Switzerland an...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 29, 2021
Lead Product(s) : BP-101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BP-101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Forte Biosciences
Deal Size : $11.1 million
Deal Type : Acquisition
Ovoca Bio plc: Acquisition of Remaining Minority Shareholding in IVIX LLC
Details : Silver Star Ltd., Ovoca's wholly-owned subsidiary, has acquired the remaining approximate 40% participation interest that it does not already own directly in the charter capital of IVIX.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
March 24, 2020
Lead Product(s) : BP-101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Forte Biosciences
Deal Size : $11.1 million
Deal Type : Acquisition
Reset All
